← board
BIVIW
distress 6/10 · elevated risk$0.35-31%today-31% from 52w high
Revenue
pre-revenue
Liquidity
$13M
Runway
0.5 yrs
Shares 1y
+0%
Price & events
+6.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-31.4%
1D
+0.0%
1W
+0.0%
1M
+0.0%
3M
—
6M
—
1Y
—
2Y
—
5Y
+6.1%
All
Overview
- Market Cap
- $2.64M
- Volume
- 0
- 52 Week Range
- $0.33 – $0.51
- Total Shares
- 7.54M
- Float Shares
- 7.50M
- Beta
- 0.57
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- 2026-05-26Small cap wrap: First Phosphate, Miivo Holdings, 1911 Gold, BioVie… - Proactive financial news
- 2026-05-09BioVie CEO shares insights into long COVID trial - ICYMI - Proactive financial news
- 2026-04-13Is trend weakening for BioVie (BIVIW) Stock | Price at $0.25, Down 4.94% - getLinesFromResByArray error: size == 0 - lwvtexas.org
- 2025-08-11BioVie Inc. Announces Closing of $12 Million Public Offering - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.